FRUZAQLA

This brand name is authorized in Austria, France, Lithuania, Romania, United States

Active ingredients

The drug FRUZAQLA contains one active pharmaceutical ingredient (API):

1 Fruquintinib UNII 49DXG3M5ZW - FRUQUINTINIB

Fruquintinib is a selective tyrosine kinase inhibitor of VEGFR-1, -2, and -3 with antitumor effects resulting from suppression of tumour angiogenesis. Read about Fruquintinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
FRUZAQLA Hard capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR
FRUZAQLA Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EK04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 63200612, 64771069
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1100271, 1100272
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W70451001, W70452001
Country: US	FDA, National Drug Code	Identifier(s): 63020-210, 63020-225